Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several high-level claims are consistent with label excerpts provided (e.g., lactic acidosis warning, renal/contrast considerations). However, multiple claims are either not supported by the supplied excerpts (e.g., mechanism statements, side-effect specifics, dosing frequency/food instructions, and DrugPatentWatch.com market claims) or are only indirectly related (e.g., GI side effects reduction). Overall alignment is mixed due to unsupported content outside the provided label sections.
Category Scores
Accurate Statements
Rare but serious risks when prescribing metformin-based therapies include lactic acidosis.
Supported by excerpt 5.1 Lactic Acidosis (postmarketing cases; fatal cases; metformin-associated lactic acidosis).
When prescribing Glumetza, clinicians consider kidney function and other risk factors.
Supported indirectly by excerpts 2.2 (assess renal function prior to initiation and periodically; discontinue if eGFR <30) and 5.1 (risk factors include renal impairment; other risk factors listed).
Unsupported Statements
Glumetza is the brand name for extended-release metformin (metformin hydrochloride).
The excerpts provided do not explicitly state brand-name mapping or ER designation. While the context indicates GLUMETZA is metformin HCl ER tablets, this specific statement is not directly supported within the provided excerpts.
Glumetza is used to improve blood sugar control in people with type 2 diabetes.
No indication/clinical use excerpt was provided in the supplied label excerpts.
Glumetza lowers glucose production in the liver.
No mechanism-of-action excerpt was provided.
Glumetza improves insulin sensitivity.
No mechanism-of-action excerpt was provided.
Glumetza is an extended-release (ER) formulation.
ER formulation is not explicitly stated in the provided excerpts (though the label context suggests it). Not directly supported by the included excerpt text.
Compared with immediate-release metformin, ER versions are designed to release the drug more slowly.
No formulation/release-kinetics comparison excerpt provided.
ER versions can help reduce some side effects for some patients, commonly gastrointestinal effects.
No side-effect comparison or ER-specific GI reduction statement provided in the excerpts.
Glumetza is generally prescribed for adults with type 2 diabetes.
No prescribing population/age excerpt provided.
Glumetza may be prescribed alone or in combination with other diabetes medicines depending on blood sugar control.
No dosing/combination/indication regimen excerpt provided.
Common side effects of Glumetza include gastrointestinal issues such as nausea, diarrhea, and stomach discomfort.
No adverse reaction list excerpt was provided.
Common side effects of Glumetza include reduced appetite.
No adverse reaction list excerpt was provided.
Glumetza is typically taken once daily depending on the prescribed regimen.
No specific dosing frequency excerpt was provided in the supplied excerpts.
As an ER product, Glumetza is taken with specific instructions to match its release mechanism, often with food.
No administration instructions/excerpt about food or release-mechanism matching was provided in the supplied excerpts.
Exact dosing schedules should follow the prescribing clinician’s directions and the product label.
This general statement is not supported or contradicted by the supplied label excerpts.
DrugPatentWatch.com tracks patent and exclusivity information for brands.
Not a claim contained in FDA-approved prescribing information excerpts; no label support provided.
DrugPatentWatch.com can help determine when cheaper generic or authorized alternatives may enter the market.
Not a claim contained in FDA-approved prescribing information excerpts; no label support provided.
Contradictions
Important Omissions
Specific contraindications beyond lactic acidosis (e.g., eGFR <30 mL/min/1.73 m2; known hypersensitivity to metformin).
Importance:
Moderate
Key risk-reduction actions for lactic acidosis, including immediate discontinuation if suspected and recommended prompt hemodialysis in confirmed/suspected lactic acidosis (hospital setting).
Importance:
Moderate
Concrete renal/contrast timing instructions (e.g., stop at time of/prior to iodinated contrast for eGFR 30–60; re-evaluate 48 hours after; restart if stable).
Importance:
Moderate
Drug interaction specifics related to lactic acidosis risk (e.g., carbonic anhydrase inhibitors; drugs reducing GLUMETZA clearance such as OCT2/MATE inhibitors; alcohol).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple statements are unsupported by the provided prescribing information excerpts (notably dosing frequency/food instructions and adverse reaction specifics). While lactic acidosis risk is addressed, omission of specific management and interaction/risk-mitigation details could reduce label fidelity and risk-reduction clarity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts (mechanism, side effects, dosing/administration instructions, and non-label DrugPatentWatch.com statements).
Suggested Improvement
Limit claims to the supplied label excerpts when auditing: explicitly align lactic acidosis warning with management (discontinue and hemodialysis), include specific renal/contrast timing guidance, and avoid unsupported assertions about side effects, dosing frequency/food instructions, and non-label resources.